Skip to main content
TENX
NASDAQ Life Sciences

10% Owner ADAR1 Capital Adds $1.38M More Tenax Stock After Phase 3 Miss

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.84
Mkt Cap
$69.234M
52W Low
$1.31
52W High
$19.4
52W Position info
40% above low
Off High info
91% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

TENX sits 40% above its 52-week low of $1.31.

Summary

10% owner ADAR1 Capital bought $1.38M more Tenax stock over three days, extending its post-trial accumulation to 5.62M shares.


Key Events · Ownership and Investor Activity · TENX

  • 10% Owner Adds $1.38M

    ADAR1 Capital Management purchased 770,333 shares at $1.79-$1.80 across three days (Aug 31-Sep 2), totaling $1,381,750.

  • Stake Rises to 5.62M Shares

    Post-transaction holdings reached 5,624,151 shares, up from 4,853,818 before this buying.

  • Follows Prior $1.81M Buy

    This extends the accumulation disclosed on Aug 24, when ADAR1 bought $1.81M following the Phase 3 LEVEL trial miss.

  • Conviction After Trial Miss

    The continued buying suggests the 10% owner sees value in the subgroup and biomarker data despite the primary endpoint failure.


Analysis · TENX · Life Sciences

ADAR1 Capital Management, a 10% owner, bought another $1.38 million of Tenax stock across three days at $1.79-$1.80, lifting its stake to 5.62 million shares. This follows a $1.81 million purchase disclosed on August 24, just days after the Phase 3 LEVEL trial missed its primary endpoint. The continued buying by a large institutional holder suggests conviction that the subgroup and biomarker data still support the oral levosimendan program, despite the headline trial failure.

How filings like this one have moved

In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TENX was trading at $1.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $69.2M. The 52-week trading range was $1.31 to $19.40. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TENX - Latest Insights

TENX
Sep 09, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.08
Real-time Price: $2.17 info
Change: +$0.0819 (+4%) info
Market Cap: $79.713M info
TENX
Sep 08, 2026, 5:16 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $2.02
Real-time Price: $2.17 info
Change: +$0.1451 (+7%) info
Market Cap: $79.713M info
TENX
Aug 24, 2026, 6:12 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $1.90
Real-time Price: $2.17 info
Change: +$0.265 (+14%) info
Market Cap: $79.713M info
TENX
Aug 10, 2026, 12:02 PM EDT
Source: Benzinga
Importance Score:
10
Price at Filing: $1.40
Real-time Price: $2.17 info
Change: +$0.770 (+55%) info
Market Cap: $79.713M info
TENX
Aug 10, 2026, 7:37 AM EDT
Source: Dow Jones Newswires
Importance Score:
10
Price at Filing: $2.03
Real-time Price: $2.17 info
Change: +$0.135 (+7%) info
Market Cap: $79.713M info